Aims: To assess three-year clinical outcome following randomised use of the second-generation Resolute zotarolimus-eluting stent (ZES) and the XIENCE V everolimus-eluting stent (EES). For Resolute ZES and randomised use, outcome data ≥3 years are relatively scarce.
Methods and results:
The TWENTE trial examined 1,391 patients with stable angina or non-ST-elevation acute coronary syndromes, of whom 21.6% were diabetics, 70.1% had complex B2 or C lesions and 77.4% had "off-label" indications for DES use. Three-year follow-up data were obtained in 1,381 patients (99.3%; 10 withdrawals). Adverse clinical events were independently adjudicated. The primary endpoint target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction and clinically indicated target vessel revascularisation, was 12.1% for Resolute ZES and 13.4% for XIENCE V EES (p=0.50). Cardiac death rates were 1.9% vs. 3.5% (p=0.06); the other individual components of TVF also showed no significant between-group differences. The rates of definite-or-probable stent thrombosis (1.4% vs. 1.6%, p=0.82) and very late stent thrombosis (0.6% vs. 0.4%, p=1.0) did not differ between the groups.
Conclusions: Three-year follow-up data of patients included in the randomised TWENTE trial demonstrated similar and sustained safety and efficacy of Resolute ZES and XIENCE V EES. 
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Introduction
Clinical follow-up data beyond two years provide valuable information on the long-term safety of drug-eluting stents (DES). The Resolute zotarolimus-eluting stent (ZES) (Medtronic Inc., Santa Rosa, CA, USA) is a second-generation DES that is widely used, but only a single randomised study, the RESOLUTE All-Comers trial, has published outcome data beyond two years 1 . The randomised TWENTE trial has previously demonstrated, in a broad study population, the non-inferiority of the Resolute ZES compared to the XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, CA, USA) 2, 3 . Meanwhile, three-year outcome data of the TWENTE trial have been obtained, which contribute significantly to the knowledge about the longer-term safety and efficacy of second-generation DES.
Methods
Study design, definitions of clinical endpoints, characteristics of patients, lesions, procedures and the one-and two-year clinical outcomes of the investigator-initiated, patient-blinded, randomised TWENTE trial (ClinicalTrials.gov NCT01066650) have been previously reported 2, 3 . The TWENTE trial enrolled 1,391 patients with stable angina or non-ST-elevation acute coronary syndromes, of whom 21.6% were diabetics, 70.1% had complex lesions and 77.4% fulfilled at least one criterion of off-label DES use 2 . More than 80% of all eligible patients were enrolled in this randomised clinical trial 4 . Between two-and three-year follow-up, the external CRO Figure 1) . The Kaplan-Meier curves of cardiac death 
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Log-rank p=0.98 Log-rank p=0.84 Follow-up (days) Cumulative incidence of stent thrombosis (%) This study was not powered to assess between-group differences in secondary clinical endpoints, such as cardiac death. In addition, our findings may not be generalised to patients with an acute ST-elevation MI (first 48 hours), as such patients were not enrolled in TWENTE.
Figure 1. Kaplan-Meier curves for the composite endpoint target vessel failure (TVF) and its individual components until three-year follow-up. (A) TVF, a composite of cardiac death, target vessel-related MI and target vessel revascularisation; (B) cardiac death; (C) target vesselrelated MI; (D) target vessel revascularisation. P-values were derived from the log-rank test; they may differ from p-values reported in the manuscript, which were derived from χ 2 analysis.
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Conclusion
The present three-year follow-up of the TWENTE trial demonstrates a similar and sustained safety and efficacy of the secondgeneration Resolute ZES and XIENCE V EES.
Impact on daily practice
The favourable three-year outcome data after use of both permanent-polymer drug-eluting stents (DES) in the broad study population of the TWENTE randomised trial, which comprised a real-world patient population with many patients who had complex lesions and various comorbid conditions, are a strong signal of sustained safety and efficacy of the compared devices in clinical practice. In addition, the consistently low rates of adverse clinical events such as stent thrombosis, target vessel-related myocardial infarction and repeat revascularisation, which were similar for both DES, represent an important benchmark for future comparison with long-term outcome data to be obtained after the use of novel DES and biodegradable scaffolds in complex patients.
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